Effects of benazepril alone and in combination with hydrochlorothiazide in comparison with felodipine extended release in elderly patients with mild- to-moderate essential hypertension

Roberto Fogari, Annalisa Zoppi, Paola Lusardi, Amedeo Mugellini, Federico Bertocchi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The aim of this study was to assess the efficacy and tolerability of two antihypertensive regimens-one using benazepril, eventually combined with hydrochlorothiazide in nonresponders, and the other using titration of felodipine extended release (ER)-in elderly patients with hypertension. After a 2-week washout period, 236 patients (127 men and 109 women aged 65 to 80 years) with mild-to-moderate essential hypertension (systolic blood pressure [SBP] ≤160 mm Hg and diastolic blood pressure [DBP] ≤95 mm Hg), were given benazepril 10 mg once daily (n = 118) or felodipine ER 5 mg once daily (n = 118) for 4 weeks, according to a multicenter, randomized, double-masked design. At the end of this treatment period, patients responding to treatment were kept at the same dose of their respective randomized drug for an additional 8 weeks. The nonresponders were given the fixed combination benazepril 10 mg plus hydrochlorothiazide 12.5 mg or felodipine ER 10 mg. Patients were examined at the end of the washout period and every 4 weeks thereafter. At each visit, sitting SBP and DBP were measured with a mercury sphygmomanometer and heart rate by radial pulse palpation. Adverse events were recorded. Both benazepril and felodipine ER were similarly effective in reducing SBP and DBP. No significant differences between the two treatment groups were observed in the mean decreases in blood pressure or in the number or percentage of patients with successful responses to treatment. Both treatments were well tolerated; the incidence of drug-related side effects, however, was slightly but significantly higher in the felodipine ER-treated group than in the benazepril group (14.4% vs 8.5%). In conclusion, benazepril 10 mg given as monotherapy, or as a fixed combination with hydrochlorothiazide in nonresponders, and felodipine ER 5 mg, titrated to 10 mg in nonresponders, were both effective and well tolerated in elderly patients with hypertension.

Original languageEnglish
Pages (from-to)246-256
Number of pages11
JournalCurrent Therapeutic Research
Volume59
Issue number4
DOIs
Publication statusPublished - 1998

Fingerprint

Felodipine
Hydrochlorothiazide
Blood Pressure
Essential Hypertension
benazepril
Sphygmomanometers
Hypertension
Therapeutics
Palpation
Drug-Related Side Effects and Adverse Reactions
Mercury
Antihypertensive Agents

Keywords

  • Benazepril
  • Elderly patients
  • Felodipine
  • Hypertension treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effects of benazepril alone and in combination with hydrochlorothiazide in comparison with felodipine extended release in elderly patients with mild- to-moderate essential hypertension. / Fogari, Roberto; Zoppi, Annalisa; Lusardi, Paola; Mugellini, Amedeo; Bertocchi, Federico.

In: Current Therapeutic Research, Vol. 59, No. 4, 1998, p. 246-256.

Research output: Contribution to journalArticle

@article{33ab04e8132847389e97e60379d712eb,
title = "Effects of benazepril alone and in combination with hydrochlorothiazide in comparison with felodipine extended release in elderly patients with mild- to-moderate essential hypertension",
abstract = "The aim of this study was to assess the efficacy and tolerability of two antihypertensive regimens-one using benazepril, eventually combined with hydrochlorothiazide in nonresponders, and the other using titration of felodipine extended release (ER)-in elderly patients with hypertension. After a 2-week washout period, 236 patients (127 men and 109 women aged 65 to 80 years) with mild-to-moderate essential hypertension (systolic blood pressure [SBP] ≤160 mm Hg and diastolic blood pressure [DBP] ≤95 mm Hg), were given benazepril 10 mg once daily (n = 118) or felodipine ER 5 mg once daily (n = 118) for 4 weeks, according to a multicenter, randomized, double-masked design. At the end of this treatment period, patients responding to treatment were kept at the same dose of their respective randomized drug for an additional 8 weeks. The nonresponders were given the fixed combination benazepril 10 mg plus hydrochlorothiazide 12.5 mg or felodipine ER 10 mg. Patients were examined at the end of the washout period and every 4 weeks thereafter. At each visit, sitting SBP and DBP were measured with a mercury sphygmomanometer and heart rate by radial pulse palpation. Adverse events were recorded. Both benazepril and felodipine ER were similarly effective in reducing SBP and DBP. No significant differences between the two treatment groups were observed in the mean decreases in blood pressure or in the number or percentage of patients with successful responses to treatment. Both treatments were well tolerated; the incidence of drug-related side effects, however, was slightly but significantly higher in the felodipine ER-treated group than in the benazepril group (14.4{\%} vs 8.5{\%}). In conclusion, benazepril 10 mg given as monotherapy, or as a fixed combination with hydrochlorothiazide in nonresponders, and felodipine ER 5 mg, titrated to 10 mg in nonresponders, were both effective and well tolerated in elderly patients with hypertension.",
keywords = "Benazepril, Elderly patients, Felodipine, Hypertension treatment",
author = "Roberto Fogari and Annalisa Zoppi and Paola Lusardi and Amedeo Mugellini and Federico Bertocchi",
year = "1998",
doi = "10.1016/S0011-393X(98)85079-0",
language = "English",
volume = "59",
pages = "246--256",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "4",

}

TY - JOUR

T1 - Effects of benazepril alone and in combination with hydrochlorothiazide in comparison with felodipine extended release in elderly patients with mild- to-moderate essential hypertension

AU - Fogari, Roberto

AU - Zoppi, Annalisa

AU - Lusardi, Paola

AU - Mugellini, Amedeo

AU - Bertocchi, Federico

PY - 1998

Y1 - 1998

N2 - The aim of this study was to assess the efficacy and tolerability of two antihypertensive regimens-one using benazepril, eventually combined with hydrochlorothiazide in nonresponders, and the other using titration of felodipine extended release (ER)-in elderly patients with hypertension. After a 2-week washout period, 236 patients (127 men and 109 women aged 65 to 80 years) with mild-to-moderate essential hypertension (systolic blood pressure [SBP] ≤160 mm Hg and diastolic blood pressure [DBP] ≤95 mm Hg), were given benazepril 10 mg once daily (n = 118) or felodipine ER 5 mg once daily (n = 118) for 4 weeks, according to a multicenter, randomized, double-masked design. At the end of this treatment period, patients responding to treatment were kept at the same dose of their respective randomized drug for an additional 8 weeks. The nonresponders were given the fixed combination benazepril 10 mg plus hydrochlorothiazide 12.5 mg or felodipine ER 10 mg. Patients were examined at the end of the washout period and every 4 weeks thereafter. At each visit, sitting SBP and DBP were measured with a mercury sphygmomanometer and heart rate by radial pulse palpation. Adverse events were recorded. Both benazepril and felodipine ER were similarly effective in reducing SBP and DBP. No significant differences between the two treatment groups were observed in the mean decreases in blood pressure or in the number or percentage of patients with successful responses to treatment. Both treatments were well tolerated; the incidence of drug-related side effects, however, was slightly but significantly higher in the felodipine ER-treated group than in the benazepril group (14.4% vs 8.5%). In conclusion, benazepril 10 mg given as monotherapy, or as a fixed combination with hydrochlorothiazide in nonresponders, and felodipine ER 5 mg, titrated to 10 mg in nonresponders, were both effective and well tolerated in elderly patients with hypertension.

AB - The aim of this study was to assess the efficacy and tolerability of two antihypertensive regimens-one using benazepril, eventually combined with hydrochlorothiazide in nonresponders, and the other using titration of felodipine extended release (ER)-in elderly patients with hypertension. After a 2-week washout period, 236 patients (127 men and 109 women aged 65 to 80 years) with mild-to-moderate essential hypertension (systolic blood pressure [SBP] ≤160 mm Hg and diastolic blood pressure [DBP] ≤95 mm Hg), were given benazepril 10 mg once daily (n = 118) or felodipine ER 5 mg once daily (n = 118) for 4 weeks, according to a multicenter, randomized, double-masked design. At the end of this treatment period, patients responding to treatment were kept at the same dose of their respective randomized drug for an additional 8 weeks. The nonresponders were given the fixed combination benazepril 10 mg plus hydrochlorothiazide 12.5 mg or felodipine ER 10 mg. Patients were examined at the end of the washout period and every 4 weeks thereafter. At each visit, sitting SBP and DBP were measured with a mercury sphygmomanometer and heart rate by radial pulse palpation. Adverse events were recorded. Both benazepril and felodipine ER were similarly effective in reducing SBP and DBP. No significant differences between the two treatment groups were observed in the mean decreases in blood pressure or in the number or percentage of patients with successful responses to treatment. Both treatments were well tolerated; the incidence of drug-related side effects, however, was slightly but significantly higher in the felodipine ER-treated group than in the benazepril group (14.4% vs 8.5%). In conclusion, benazepril 10 mg given as monotherapy, or as a fixed combination with hydrochlorothiazide in nonresponders, and felodipine ER 5 mg, titrated to 10 mg in nonresponders, were both effective and well tolerated in elderly patients with hypertension.

KW - Benazepril

KW - Elderly patients

KW - Felodipine

KW - Hypertension treatment

UR - http://www.scopus.com/inward/record.url?scp=0031966226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031966226&partnerID=8YFLogxK

U2 - 10.1016/S0011-393X(98)85079-0

DO - 10.1016/S0011-393X(98)85079-0

M3 - Article

VL - 59

SP - 246

EP - 256

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 4

ER -